Smarter SLRs or Risky Shortcuts? Perspectives From Global HTA Stakeholders

As a follow up to our recent ISPOR-sponsored webinar, this whitepaper explores a critical and timely question in health technology assessment:

How do HTA agencies view the integration of AI into SLRs?

Given the growing demand for faster, more efficient evidence synthesis, the use of AI holds clear promise. But that promise comes with a caveat—HTA agencies are proceeding cautiously.

Read our whitepaper for updated findings on current guidance from HTA agencies on AI use, along with real-world perspectives from HTA stakeholders.

Key highlights include:

Only three agencies, CDA‑AMC (Canada), NICE (UK), and IQWiG (Germany), currently issue any specific recommendations on using AI in SLRs, each highlighting transparency and the necessity of human oversight
Surveyed HTA professionals cited efficiency as AI’s primary advantage in SLRs, yet remained skeptical about its ability to reduce bias, emphasizing the importance of transparency and reproducibility

We are excited to share our latest thinking with you.

Please fill out the form to download the whitepaper.

"*" indicates required fields

Facebook

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company Name*

Job Title*

Work Email*

Select the solutions you’re interested in (if any)

By submitting your information, you agree to receive communications from OPEN Health. We will use your information in accordance with our Privacy Notice.

At OPEN Health, we connect visionary minds, pioneering science, and advanced technology to drive real impact.

By uniting people, science, and technology, we activate new opportunities for biopharma innovation. Our expertise across medical affairs and market access unlocks faster, smarter routes to market. We are committed to improving patient outcomes worldwide.

Talk to us